Oncology for the Inquisitive Mind

Guest Interview - Professor Enrique Grande Prof Enrique Grande, a medical oncologist from Madrid, Spain, is our guest this week. Prof Grande is not your average oncologist nor your average podcast guest with a fascinating back story, a varied career and the charisma and wisdom to match! Prof Grande has worked in all facets of oncology, including industry and is helping transform how patients access oncology care in Spain. He is the director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Cancer Center Madrid - Hospiten. Prof Grande strongly focused on genitourinary and endocrine cancer research and was awarded his PhD in pharmacokinetic and pharmacodynamics study of tyrosine kinase inhibitors in liver metabolism. Listen on, and you will learn everything you need to know about bladder cancer and medical oncology. #cancer #oncology #madrid MD Anderson Cancer Center #BladderCancer #EV302 #NIAGARA #ADC #immunotherapy https://lnkd.in/gtE8PQ7y

I'm excited to share my recent appearance on Inquisitive Oncology/Oncology for the Inquisitive Mind Joshua HurwitzMichael Fernando. In this episode, I discuss the growth of palliative care and its importance in enhancing the quality of life for cancer patients. Reflecting on my experiences and the ongoing work needed to support patients and their families effectively was a privilege. You can listen to the episode here:  https://lnkd.in/efd_gDxv    For more about my work or to subscribe to my palliative care newsletter, visit janetabrahm.com. #PalliativeCare #Oncology #CancerTreatment #SupportiveCare #Healthcare

#ESMO24 review with Dr Ned McNamee from St Vincent's Health Australia Lung cancer treatment has changed seismically since 2018, and the NEJM Group publication of Keynote 189. This week, we have Dr Ned Mcnamee on the show to give us his highlights of lung cancer updates from ESMO 2024. He explores the resectable lung cancer space with Checkmate-77T, crosses the ADRIATIC trial in patients with limited-stage small cell lung cancer, and brings in a home run with an updated LAURA trial perspective(osimertinib after definitive chemoradiotherapy). Links to studies discussed in this episode #Checkmate77T #ADRIATIC #LAURA Special Mentions #Dedication1 #Mariposa2 https://lnkd.in/gjbpczBy The Kinghorn Cancer Centre St Vincent’s Health Network Sydney Westmead Hospital Jordan Cohen #cancer #lungcancer #osimertinib #durvalumab #procan CMRI Hospital

#ESMO24 review with Professor Anthony Joshua from The Kinghorn Cancer Centre #ESMO24 was the year genitourinary cancer took front and centre stage with many exciting updates, trials, and tribulations. This week, OFTIM brings its greatest champion back to dive deep into the changes that will impact our patients and their families, the NCCN guidelines, and how we practice medicine. Unfortunately, the heavyweight champion boxer was unavailable, but we got the next best thing - Prof Anthony Joshua from St Vincent’s Health Network Sydney and Garvan Institute of Medical Research. This week, he discusses all things genitourinary cancer and gives a knockout performance. Enough boxing analogies - on with the show! Links to studies discussed in this episode (subscription may be required): #PATCH+ #STAMPEDE #ARANOTE #STAMPEDE (metformin Arm) #PEACE3 #SPLASH #NIAGARA #AMBASSADOR #TiNivo2 https://lnkd.in/gGCHQ4sH #genitourinarycancers #prostatecancer #bladdercancer #renalcancer #curecancer #trials #medicaleducation #runakilometerinunderfourminutesandthirtyseconds

#ESMO24 review with Dr Geoffrey Chong from Austin Health Oncology is ever-changing and increasingly complex. It's hard to see the forest through the trees. With ESMO 24 firmly in the rearview mirror, the dust settling, and the end of the year closing in, Michael and Josh take one final look at the trials that may change practice, direct research, or are generally interesting. This week, we interviewed Dr Geoffrey Chong, a medical oncologist specialising in gastrointestinal cancers who currently holds appointments at the Olivia Newton-John Cancer Research Institute, Grampians Health and the University of Melbourne. #colorectalcancer #curecancer #moonshot Enjoy! https://lnkd.in/gPzadbMZ Links to studies discussed in this episode (subscription may be required): #APOLLO #LEAP012 #CABINET #INTERAACT2 #MOONLIGHT #NICHE2 #NICHE3 #TOPGEAR #RAMTAS #SOLARIS

A huge thanks to everyone who came to Oncology for the Inquisitive Mind's premiere in-person event, the Art of Breast Cancer at Supernormal last night. The turnout was fantastic, the discussion was engaging, and the food was incredible. Thanks to Belinda Yeo, Richard De Boer, Frances Barnett and Michael Green for lending their expertise to this wonderful evening. And of course, massive thanks to our sponsors from Merck Healthcare, Pfizer, Gilead Sciences and Eisai Co., Ltd. for making the event possible. If you are in Melbourne, keep an eye out for future events brought to you by Joshua Hurwitz and Michael Fernando!

#ESMO24 - Plenary Episode We have finally come to the end of #ESMO2024. As is now tradition, Michael and Josh conclude their epic journey with a special episode highlighting their absolute favourite practice-changing selections from the Plenary Sessions. ESMO - European Society for Medical Oncology brought a selection of wonderful studies that genuinely deserve the title "practice changing." Thank you to everyone who joined us on this amazing journey. We are so privileged to be able to share these results with you. Stay tuned to Oncology for the Inquisitive Mind in the coming weeks as we will be starting our #ESMO2024: Retrospective miniseries, where we speak to Australian and international experts in the areas of breast, lung, GI, GU and skin cancers and get their opinions on the goings on in Barcelona. #PEACE3 #PODIUM #KEYNOTEA18 #KEYNOTE522 OS Data #NIAGARA Note: this episode was recorded over two days at two separate locations. https://lnkd.in/gcYZiejS

#ESMO24 - Day 3 Episode Day three of ESMO - European Society for Medical Oncology Congress had many exciting trials in the #genitourinarycancer space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy. They investigate biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma. While ESMO is finishing, and everyone is jet-setting home, this congress raises many more questions than answers - see you all in Berlin 2025... https://lnkd.in/gCS6fXV8 DV001 (Disitamab vedotin (DV) + pembrolizumab in treatment-naïve HER2-expressing LA/met UC) EV-302 - nectin four expression UpFrontPSMA Study Splash Study (Lu-PNT2002)

#ESMO24 - Day 2 Episode Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the ESMO - European Society for Medical Oncology #congress. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supportive care to head and neck cancer and so many other fascinating studies in between. Read on to listen to the boys' best bits from Barcelona on Day 2 of ESMO. Studies discussed in this episode: 1. Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study 2. ERICA study (WJOG14320B) 3. JCOG1008 4. RADIO trial (LASCCHN) 5. ShortHER 6. Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study 7. GALAXIES Lung-201: belrestotug + dostarlimab 8. Ivonescimab +/- ligufalimab + FOLFOXIRI as 1L treatment for mCRC 9. NATALEE https://lnkd.in/gCkCKwwz

#ESMO24 - Day 1 Episode The European Society of Medical Oncology Congress has begun, and Michael and Josh are on the ground, bringing you breaking studies and some heartbreaks. Today, they look at hepatocellular carcinoma (HCC), renal cancers, and breast cancer, an eclectic but exciting mix of cancer types. Michael investigates HCC treatment with iparomlimab and tuvonaralimab with bevacizumab in a first-line setting, along with some updated efficacy from the IMbrave050 trial. He finishes off his whirlwind tour of day one by summarising some interesting education points in the metastatic colorectal cancer space. Josh looks at Tivozanib-Nivolumab in advanced RCC following immunotherapy, along with another trial where Belzutifan may be another treatment option. He finishes up with HER3-directed therapy! Phs II/III DUBHE-H-308 Imbrave050 (HCC) TiNivo-2 Study (mRCC) Litespark 005 (mRCC) Checkmate 8HW (mCRC) Icarus-Breast 01 (mBreast Cancer) #breastcancer #renalcancer #hepatocellularcarcinoma ESMO - European Society for Medical Oncology #education #podcast #cancertreatment #curecancer https://lnkd.in/gE3egEQS